Loading, Please wait ...

Please contact us if you would like to upgrade your account to include access to financial models

Please contact us if you would like to upgrade your account to include short term strategies for this stock.

WCRX.O

ISIN: BMG9435N1083
SEDOL: B1FJRX0

Rating:

BUY

Target Price:

16.29 USD

Investment Horizon:

6 to 12 months
11th May 2009 View Report   Download

1Q 09 News Alert

Warner Chilcott Limited (Warner Chilcott) reported revenues in-line with our estimate for 1Q 09. Operating and net margins exceeded our expectations in 1Q 09. We believe the company will continue to report strong top-line growth, going forward, driven by strong demand for Doryx, Leostrin 24 FE and Femcon FE. Consequently, our outlook for the company remains broadly unchanged and we reiterate our BUY rating for the common stock....

1st Apr 2009 View Report   Download

4Q 08 & FY 2008 Update Report

Warner Chilcott settled both Femcon and Loestrin 24 FE patent cases during the first quarter of FY 2009, with favorable terms for the company. Actavis Elizabeth LLC (Actavis) submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for approval to manufacture and sell generic versions of DORYX 100 mg and 75 mg delayed-release tablets…

2nd Mar 2009 View Report   Download

4Q 08 & FY 2008 News Alert

Warner Chilcott Limited (Warner Chilcott) reported revenues in-line with our estimate for 4Q 08. Performance at the operating and net levels exceeded our expectations in 4Q 08. We believe the company will continue to report strong top-line growth, going forward, driven by strong demand for Taclonex, Doryx, Leostrin 24 FE and Femcon FE. Consequently, our outlook for the company remains broadly unchanged and we reiterate our BUY rating…

28th Jan 2009 View Report   Download

Company News Alert

CLICK VIEW REPORT TO READ FREE REPORT

On 27 January 2009, Warner Chilcott Limited (Warner Chilcott) announced its guidance for FY 2009. The company’s FY 2009 top-line and gross margin guidance is broadly in line with our estimates for FY 2009, while the company’s GAAP net income forecasts are reported figures and, hence, are not directly comparable with our adjusted operating and net income estimates for FY 2009. Nevertheless, our outlook for the company remains…

26th Nov 2008 View Report   Download

3Q 08 Update Report

CLICK VIEW REPORT TO READ FREE REPORT

Warner Chilcott Ltd. (Warner Chilcott) reported modest revenue growth, in-line with our estimate, driven by strong performance from Dermatology products in 3Q 08. The increasing demand and wider acceptance of Doryx and Taclonex should continue to support revenues in FY 2008 and FY 2009. We believe the successful launch of Taclonex will offset the negative impact of Dovonex patent expiry, while focus on…